Nuformix (LON:NFX) Trading 17.6% Higher – Still a Buy?

Shares of Nuformix plc (LON:NFX) traded up 17.6% on Tuesday . The company traded as high as GBX 0.30 and last traded at GBX 0.30. 29,456,109 shares traded hands during mid-day trading, a decline of 23% from the average session volume of 38,018,152 shares. The stock had previously closed at GBX 0.26.

Nuformix Trading Up 17.6%

The stock has a 50 day simple moving average of GBX 0.26 and a 200-day simple moving average of GBX 0.23. The firm has a market capitalization of £6.33 million, a P/E ratio of -7.63 and a beta of 1.22.

Nuformix (LON:NFX) last issued its quarterly earnings data on Tuesday, January 27th. The company reported GBX (0.04) earnings per share for the quarter.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.